Critical Issues in Communication and Individualizing Treatment for Patients...
Video Module - In this interactive program, John L. Marshall, MD, and Daniel Z. Sands, MD, MPH, FACP, FACMI, provide expert perspective on colorectal cancer treatment, apply the latest clinical data on...
View ArticlePatient Resource Directory – Colorectal Cancer
PDF - Download this handout to give to your patients to help guide them on important questions to ask at their next visit, provide them with a list of advocacy and peer support websites and general...
View Article2015 Gastrointestinal Cancers Symposium
Learning Module - George A. Fisher, MD, PhD, explores key recent data that promise to improve the treatment of patients with colorectal, gastric, and pancreatic cancers.
View ArticleGastrointestinal Cancers
Slideset - In this downloadable slideset, George A. Fisher, MD, PhD, reviews key studies and data relevant to the management of patients with GI cancers presented at the 2015 GI American Society of...
View ArticleTumors Deficient in Mismatch Repair Particularly Susceptible to Immune...
Slideset - Results of the first study utilizing tumor genetics to guide use of immunotherapy suggest that genomic instability may be more important than histology in conferring response to anti–PD-1...
View ArticleTumors Deficient in Mismatch Repair Particularly Susceptible to Immune...
Slideset - Results of the first study utilizing tumor genetics to guide use of immunotherapy suggest that genomic instability may be more important than histology in conferring response to anti–PD-1...
View ArticleSIRFLOX: Addition of SIRT to mFOLFOX6 ± Bevacizumab in First-line mCRC...
Slideset - Addition of SIRT to chemotherapy first-line treatment of metastatic CRC did not improve overall PFS or ORR, but substantially reduced the risk of disease progression in the liver.
View ArticleAspirin Associated With Reduced Mortality in Patients With CRC
Slideset - The largest cohort ever to examine the effects of aspirin as secondary prevention reveals that aspirin independently reduces the risk of both CRC-specific mortality and all-cause mortality.
View ArticleColorectal Cancer: Individualizing Therapy Beyond Second-line Treatment
Video Module - In this interactive online program, John L. Marshall, MD, discusses the application of the latest clinical data on therapeutic choices for patients with CRC that has progressed after 2...
View ArticleColorectal Cancer: Individualizing Therapy Beyond Second-line Treatment
Slideset - In this downloadable slideset, John L. Marshall, MD, provides a comprehensive look at current options for patients with colorectal cancer who fail first-line therapy.
View ArticleMy Thoughts on Molecular Profiling in Colorectal Cancer
ClinicalThought Discussion - How I use molecular profiling when selecting frontline treatment for metastatic colorectal cancer.
View ArticleTumor Location Prognostic and Predictive in KRAS wt mCRC: Retrospective...
Slideset - Tumor location appears to be prognostic of PFS, OS, and predictive of response to biologic agents in KRAS wt mCRC.
View ArticlePembrolizumab Shows Promising Activity in Mismatch Repair–Deficient CRC
Slideset - Updated data in patients with mismatch repair–deficient metastatic CRC show potential association with treatment response to pembrolizumab.
View ArticlePembrolizumab Shows Promising Activity in Mismatch Repair–Deficient CRC
Slideset - Updated data in patients with mismatch repair–deficient metastatic CRC show potential association with treatment response to pembrolizumab.
View ArticleCobimetinib + Atezolizumab Well Tolerated and Shows Promising Activity in...
Slideset - MEK and PD-L1 inhibitors show potential synergy in MSS and chemorefractory KRAS-mutant mCRC.
View ArticleCobimetinib + Atezolizumab Well Tolerated and Shows Promising Activity in...
Slideset - MEK and PD-L1 inhibitors show potential synergy in MSS and chemorefractory KRAS-mutant mCRC.
View ArticleBiologic Therapies in Metastatic Colorectal Cancer: Mastering Your Moves...
ClinicalThought Discussion - Selecting therapies for metastatic CRC through subsequent lines of therapy can often feel like a chess match. Here’s my approach.
View ArticleTrifluridine/Tipiracil (TAS-102) Improves Survival in Patients With...
Slideset - Subanalysis of phase III RECOURSE trial suggests clinical benefit of TAS-102 in specific patients with metastatic CRC.
View ArticleImmunoscore Prognostic in Colon Cancer
Slideset - Immunoscore found to be predictive of time to recurrence, disease-free survival, and OS in colon cancer.
View ArticleImmunoscore Prognostic in Colon Cancer
Slideset - Immunoscore found to be predictive of time to recurrence, disease-free survival, and OS in colon cancer.
View Article
